Angelalign Technology Inc. (Angelalign) has signed two three-year framework agreements effective 1 January 2027 that govern continuing connected transactions with key related parties.

Under the 2027-2029 Clear Aligners Purchase and Sales Framework Agreement, wholly owned subsidiary Wuxi EA will supply clear aligners, intraoral scanners and related products to CC Dental Group, a distributor controlled by Angelalign’s controlling shareholder CareCapital Group. The annual transaction caps are set at RMB275.00 million, RMB360.00 million and RMB465.00 million for 2027, 2028 and 2029 respectively.

Management cited robust historical growth—revenues rose 32.55% year-on-year to RMB140.50 million in 2025 and expanded a further 53.03% in the first five months of 2026 to RMB46.20 million—as the basis for the new limits, projecting roughly 30% annual growth plus an 8% buffer. Because the applicable percentage ratios exceed 5%, the arrangement requires reporting, annual review, public disclosure and independent shareholders’ approval under Hong Kong Listing Rule 14A.

Separately, Wuxi EA entered a 2027-2029 Product Purchase Cooperation Framework Agreement with Shanghai Kaihao—40% owned by substantial shareholder Ms. Li—to source raw materials for clear-aligner production. Annual purchase caps are RMB72.00 million, RMB86.00 million and RMB95.00 million for 2027-2029, compared with historical purchases of RMB24.60 million in the second half of 2025 and RMB21.20 million in the first five months of 2026. The transaction falls between the 0.1% and 5% ratio thresholds, making it subject to reporting, annual review and announcement requirements but exempt from independent shareholders’ approval.

Angelalign stated that CC Dental’s nationwide distribution network will support market expansion—particularly in lower-tier Chinese cities—while the longer-term contract with Shanghai Kaihao secures reliable raw-material supply amid rising production demand. The board’s independent non-executive directors deem both agreements ordinary, on normal commercial terms and in the interests of shareholders.

Directors linked to CareCapital abstained from voting on the CC Dental agreement. Gram Capital has been appointed independent financial adviser, and a circular containing full details and the EGM notice will follow.

The company has reiterated monthly monitoring, external audit reviews and pricing benchmarks against independent third parties to ensure compliance with its connected-transaction policies and Hong Kong Listing Rules.